Clinical trials: Flu
Influenza Vaccination
PROmotion of FLU Vaccine Uptake in the Emergency Department - PROFLUVAXED
The goal of this research is to increase influenza vaccine acceptance and uptake in vulnerable populations whose primary (and often only) health care access occurs in emergency departments (ED Usual Source of Care Patients).
- Trial name
- PROFLUVAXED (NCT05836818)
- Testing
- Question (Q), Messaging (M)
- Where
- 8 sites in United States
- Volunteers
- 776 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Respiratory Syncytial Virus (RSV), Influenza A(H5N1)
Study of Different Formulations of Vaccines Encoding the RSV Monovalent Antigen or the Flu H5 Antigen in Participants 18 to 49 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of vaccines encoding the RSV monovalent antigen or the Flu hemagglutinin subtype 5 (H5) antigen in healthy participants aged 18 to…
- Trial name
- NCT07516418
- Testing
- H5 Flu Investigational Medical Product (IMP) 1, H5 Flu IMP 2, H5 Flu IMP 3
- Where
- 6 sites in Australia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Sanofi
Human Influenza
Bangladesh Secondary Transmission Handwashing Protocol
The next influenza pandemic is expected to spread rapidly in resource-poor settings. Influenza viruses spread from human-to-human via large respiratory droplets.
- Trial name
- NCT00880659
- Testing
- Soap
- Where
- Bangladesh
- Volunteers
- 6,600 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Influenza, Human, Influenza, Human Prevention
Phase III Clinical Trial of Quadrivalent Influenza Virus Split Vaccine
This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above).
- Conditions
- Influenza, Human, Influenza, Human Prevention, Influenza a, Influenza B
- Trial name
- NCT06800950
- Testing
- QIV, QIV Control
- Where
- 3 sites in China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Influenza
Study to Compare Self-administered and Nurse-administered Intradermal Influenza Vaccine
The purpose of this study is to compare the immunogenicity and reactogenicity of self-administered intradermal influenza vaccine (Intanza)to nurse-administered.
- Trial name
- NCT01224613
- Testing
- Intanza
- Where
- 2 sites in Canada
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Dalhousie University
Influenza
CSL H1N1 Influenza Vaccine Administered at Two Dose Levels in Adult and Elderly Populations
The purpose of this study is to assess the safety and immune response (body's defense against disease) to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT00943488
- Testing
- Inactivated H1N1 Vaccine
- Where
- 4 sites in United States
- Volunteers
- 408 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults
The purpose of this study is to determine the immune response of three dose levels of the Quadrivalent VLP vaccine in healthy young (18-49) adults. The study is broken down into four treatment groups.
- Trial name
- NCT02307851
- Testing
- Quadrivalent VLP Vaccine, Comparator TIV
- Where
- 5 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS CoV-2 Infection, Influenza -Like Illness
A Trial of Two Mask Systems in Preventing SARS CoV-2 in Healthcare Workers (HCW)
A cluster randomized trial will be conducted to evaluate the difference between an Acteev™ system (Acteev™ N95 masks YQD8008 during shifts+ Acteev™ fabric masks in community) and a standard system (standard N95 masks during…
- Trial name
- NCT05036941
- Testing
- Acteev™ Masks, Comparison Masks
- Where
- India
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- Ascend Performance Materials
Influenza
Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine
Primary objective: Immunogenicity To demonstrate that the influenza vaccine administered by intradermal route at least as immunogenic as the adjuvanted influenza vaccine administered by intramuscular route at the same dosage in…
- Trial name
- NCT00554333
- Testing
- Flu-ID 15μg, Inactivated adjuvanted Influenza Vaccine
- Where
- 8 sites in Belgium, France
- Volunteers
- 795 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Polysaccharide Vaccine, Influenza Vaccines
Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung Cancer
Postoperative pneumonia (POP) affects 4%-24% of lung cancer surgery patients, increasing mortality, stay, costs and worsening prognosis, especially in older patients.
- Conditions
- Pneumococcal Polysaccharide Vaccine, Influenza Vaccines, Preoperative, Lung Resection Surgery
- Trial name
- NCT07885540
- Testing
- 23-valent pneumococcal polysaccharide vaccine, Quadrivalent split-virion influenza vaccine
- Volunteers
- 1,278 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Egg Allergy
Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs
The objective of this study is to verify the clinical tolerance to the vaccine Flumist (intranasal live attenuated influenza vaccine) in a population of egg allergic children.
- Trial name
- NCT02142491
- Where
- Canada
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- St. Justine's Hospital
Vaccine Reaction
Effect of High-Dose Quadrivalent Influenza Vaccine (Efluelda®) Versus Standard-Dose (QIV-SD), in Subjects 65 Years of Age and Older on Innate Immunity, Including Gene Expression
The purpose of the study is to evaluate innate and adaptive immunity following QIV-HD vaccination compared to QIV-SD vaccination in people 65 years of age and older.
- Trial name
- INFLUOMICS (NCT05154383)
- Testing
- Experimental arm : High-Dose Quadrivalent Influenza Vaccine (Efluelda), Active Comparator: Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Annecy Genevois
Influenza
Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above
The purpose of this study is to evaluate the safety and immunogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Southern hemisphere) in adults (18 to 60 years of age) and in the elderly…
- Trial name
- NCT02369341
- Testing
- Fluarix Tetra
- Where
- 2 sites in Brazil
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
To determine the tolerability and safety of FLUVAL P monovalent influenza vaccine in children.
- Trial name
- NCT01100294
- Testing
- Vaccination with FLUVAL P
- Where
- Hungary
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
A Double-Dose Safety Study of An Influenza Vaccine (Multimeric-001) Injected to Elderly Volunteers
This is a phase I/II, randomized, single-blind, placebo-controlled escalating double-dose study of the safety and priming potential of an intramuscular Influenza vaccine (Multimeric-001) injected to elderly volunteers.
- Trial name
- NCT01010737
- Testing
- Multimeric-001 250 mcg, Adjuvanted Multimeric-001 250mcg, Adjuvant: Montonide isa 51 VG
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza
Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus
This will be a randomized, open-label, pilot feasibility study of four 2-dose vaccine regimens in healthy volunteers using two commercially available seasonal influenza vaccines to compare immune responses and in vitro…
- Trial name
- NCT01044095
- Testing
- FluMist® live, attenuated, intranasal seasonal influenza vaccine, Fluzone® inactivated influenza virus vaccine
- Where
- Thailand
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Armed Forces Research Institute of Medical Sciences, Thailand
Influenza Infection
A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine
The purpose of this study is to assess the safety and the body's immune response to an experimental H1N1 influenza vaccine in healthy adult and elderly populations.
- Trial name
- NCT01201902
- Testing
- Adjuvanted influenza A(H1N1) vaccine, un-adjuvanted influenza A(H1N1) vaccine
- Volunteers
- 592 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Influenza
Pandemic Influenza Plasmid DNA Vaccines (Needle)
The trial will enroll up to 57 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine.
- Trial name
- NCT00709800
- Testing
- VCL-IPT1, VCL-IPM1, PBS
- Where
- 3 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Vical
Pandemic Influenza Vaccine, Prevention
Safety and Immunogenicity of Booster Dose of An Inactivated,Adjuvanted Whole-Virion Pandemic Influenza(H5N1)Vaccine
A single center, non-randomized clinical trial in two-dose primed healthy adults to evaluate the safety and immunogenicity of a booster dose of an inactivated pandemic influenza (H5N1) vaccine (whole-virion, aluminium-adjuvanted).
- Conditions
- Pandemic Influenza Vaccine, Prevention, Pandemic Influenza
- Trial name
- NCT00660257
- Testing
- pandemic influenza vaccine (H5N1 strain NIBRG-14)
- Where
- China
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Safety and Immunogenicity of the 2005-2006 Fluzone® Vaccine
To describe the safety during Days 0 to 21 following injection of the 2005-2006 formulation of the inactivated, split-virion influenza vaccine Fluzone in subjects aged 18-59 years and subjects aged ≥ 60 years.
- Trial name
- NCT00258830
- Testing
- Fluzone®: Influenza Virus Vaccine
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.